A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a groundbreaking advance in influenza therapy, according to a study by the Institute for Biomedical Sciences at Georgia State University.
The antiviral drug blocks RNA polymerase, the enzyme that plays a central role in replicating the genome of influenza virus, causing mutations in the viral genome. If enough mutations occur, the genome becomes nonfunctional and the virus cannot replicate. The findings were published online on Oct. 23 in Science Translational Medicine.
“The compound is highly efficacious against influenza,” said Dr. Richard Plemper, senior author of the study and a professor in the Institute for Biomedical Sciences. “It’s orally available, it’s broad spectrum against all influenza virus strains tested, and most important it establishes a high barrier against viral escape from inhibition.”
Influenza, caused by a contagious respiratory virus, is characterized by fever, cough, headache, muscle and joint pain, severe malaise, sore throat and sometimes gastrointestinal symptoms. Patients in higher risk groups, such as older adults and individuals with compromised immune systems, frequently require hospitalization. Each year, seasonal influenza results in 30,000 to 80,000 fatalities in the United States. The seasonal flu vaccine is only moderately effective, and licensed antivirals are compromised by rapidly emerging viral resistance to the drugs.
In the study, the new antiviral drug was tested in ferrets, the most informative animal model for human influenza disease, against various strains that include seasonal and pandemic viruses, such as the swine-origin influenza virus responsible for a 2009 pandemic. The researchers found that the antiviral drug efficiently inhibited replication of all of these strains. Virus burden dropped rapidly after treatment, and the duration of fever was significantly shorter in treated ferrets than in control animals that did not receive the drug.
“We think that the next generation of influenza antiviral drugs must not only be efficacious and safe, but also address the resistance problem,” said Dr. Mart Toots, first author of the study and a research assistant professor associated with Dr. Plemper’s lab in the Institute for Biomedical Sciences.
That is where the new drug comes in. Through a combination of conventional and ultra-deep sequencing, Toots has demonstrated in collaboration with Dr. Alex Greninger at the University of Washington that it is very challenging for the virus to find a viable way to avoid the compound.
“We have not identified specific resistance mutations yet and are confident to say that the genetic barrier against viral resistance is high,” Plemper said. “We believe that this compound has high clinical potential as a next-generation influenza drug that combines key antiviral features.”
The Latest on: Influenza
via Google News
The Latest on: Influenza
- IFN-κ suppresses the replication of influenza A viruses through the IFNAR-MAPK-Fos-CHD6 axison April 7, 2020 at 11:55 am
He et al. found that IFN-κ was produced in the lungs of mice early after infection with various influenza A viruses (IAVs). In cultured human lung epithelial cells, IFN-κ inhibited IAV replication by ...
- COLUMN-Coronavirus lockdowns: can we learn from the 1918 influenza pandemic? Kempon April 7, 2020 at 6:56 am
Lockdowns have brought most of the world's advanced economies to a near standstill as policymakers fight the coronavirus pandemic by banning all but essential movement outside the home. Lockdowns have ...
- SARS-CoV-2 detection in patients with influenza-like illnesson April 7, 2020 at 2:39 am
We re-analysed 640 throat swabs collected from patients in Wuhan with influenza-like-illness from 6 October 2019 to 21 January 2020 and found that 9 of the 640 throat swabs were positive for ...
- US Influenza Activity Dropping, but Hospitalizations Up, CDC Sayson April 7, 2020 at 2:04 am
Influenza activity is decreasing in the United States, but hospitalization rates rose slightly, according to an April 3 report from the Centers for Disease Control and Prevention (CDC). The number of ...
- Pandemic Influenza Vaccine Market Research Report 2019-2025: By Product, Application, Manufacturer, Sales and Segmentationon April 7, 2020 at 1:49 am
The report provides rational insights along with historical and forecast data to said in better understanding of ...
- Lessons learned in Denver from 1918 influenza pandemicon April 6, 2020 at 7:48 pm
As World War I was coming to an end, a new war of a different kind was just beginning in Colorado. A deadly influenza pandemic spread across Colorado and around the world in 1918.
- What Can Images of the 1918 Influenza Pandemic Teach Us About COVID-19?on April 6, 2020 at 2:58 pm
Policemen in Seattle, Washington, wearing masks made by the Seattle Chapter of the Red Cross, during the influenza epidemic (all images courtesy the National Archives Catalog) In 1918, a flu pandemic ...
- Explained: The Japanese anti-influenza drug being tested for treating COVID-19on April 5, 2020 at 7:37 am
As there is still no specific cure for COVID-19, medicines used for other ailments are being repurposed around the world for it.
- 'Equine influenza prepared NSW racing industry for COVID-19'on April 3, 2020 at 6:03 pm
Racing NSW Chief Steward Marc Van Gestel says the equine influenza outbreak of 2007 helped prepare the industry for the impacts of the COVID-19 pandemic.
- Adiponectin exacerbates influenza infection in elderly individuals via IL-18on April 2, 2020 at 3:05 pm
In summary, our data point to a new detrimental role for the hormone adiponectin in aged lung tissue during influenza infection. Adiponectin signaling seems to have no effect on healthy and infected ...
via Bing News